Drug Targets DNA Damage to Treat Alzheimer's

A study published in *FEBS Open Bio* reveals that the accumulation of DNA damage in brain neurons may play a pivotal role in the progression of Alzheimer’s disease, offering new insights into potential therapeutic strategies. Researchers investigated the impact of targeting this DNA damage pathway using a drug designed to enhance DNA repair mechanisms, demonstrating promising results in preclinical models. The findings suggest that interventions aimed at mitigating neuronal DNA damage could slow or halt the neurodegenerative processes underlying Alzheimer’s.

The research team, led by scientists from multiple institutions, conducted experiments using a mouse model of Alzheimer’s and human brain tissue samples. They identified elevated levels of DNA damage in neurons from individuals with Alzheimer’s, correlating with disease severity. Administration of the experimental drug, which activates enzymes involved in DNA repair, reduced pathological markers such as amyloid-beta plaques and neurofibrillary tangles while improving cognitive function in mice. The authors emphasize that this approach addresses a previously underexplored aspect of Alzheimer’s pathology, potentially complementing existing treatments focused on protein clearance.

While the results are preliminary, the study highlights the therapeutic potential of DNA repair enhancement in neurodegenerative disorders. The researchers caution that further studies, including clinical trials, are necessary to assess safety and efficacy in humans. If validated, this strategy could represent a significant advancement in Alzheimer’s treatment, offering hope for addressing the root causes of the disease rather than merely managing symptoms.